Identification of autoantibody against beta-amyloid peptide in the serum of elderly.

Alzheimer's disease (AD) is characterized by two major neurological features: amyloid deposits and neurofibrillary tangles in the brain. According to the amyloid cascade hypothesis, accumulation of amyloid-beta peptide (A-beta) plays a central role in the pathogenesis of AD. Several lines of evidence suggest that antibodies against A-beta play a protective role in the neuropathology of AD. In this study, we describe the purification of an autoantibody against A-beta from human serum using affinity purification method. The purified autoantibody recognized A-beta deposits in the brain of aged Tg2676 mice, an animal model of AD. The serum levels of anti-A-beta autoantibody correlated inversely with age in both AD patients and control non-demented elderly subjects. Furthermore, the levels were significantly lower in AD patients compared with the age-matched control subjects. It is the first time to show the identification of endogenous anti-A-beta autoantibody in human serum and suggesting that serum levels of anti-A-beta autoantibody might be a good biomarker for AD patients.

Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice.

Both active and passive immunization to eliminate amyloid plaques from the brain of patients with Alzheimer's disease (AD) have confirmed that amyloid beta (Abeta) vaccination does not only result in clearance of Abeta plaques but improves behavioral-cognitive deficits in animal models of AD. In the present study, the levels of naturally occurring serum antibodies against Abeta were measured in Tg2576 mice at various ages using ELISA to determine the relationship between aging and the level of anti-Abeta autoantibody. The level of anti-Abeta antibody fell significantly at the age of 9 months, at the age when amyloid plaques started to appear in the brain of Tg2576 mice, and was persistently low thereafter. However, serum immunoglobulin (Ig) level was elevated in older transgenic mice compared with younger transgenic mice suggesting that the reduced level of anti-Abeta autoantibody was not merely due to deterioration of the immune response in aged Tg2576 mice.